Nashville, Tenn. Sept. 24, 2025 — SCRI Oncology Partners, a leading cancer treatment center led by internationally renowned oncology experts, proudly announces the opening of its new Center for Breast Health, featuring a specialized High-Risk Clinic. This comprehensive program is designed to provide all-encompassing personalized care focused on risk assessment, prevention, early detection, and advanced treatment for individuals with breast health concerns.
The center offers seamless access to leading medical and surgical oncologists, along with a full suite of services—all in one centralized location. These include personalized risk assessments, genetic testing for hereditary cancer, tailored surveillance plans, risk-reduction strategies, and opportunities to participate in both prevention-focused and treatment-specific clinical trials conducted through a collaboration with Sarah Cannon Research Institute (SCRI).
“Our mission is to deliver cutting-edge care and empower our community and individuals to become advocates for their own health and provide them with the tools and support they need to address breast health concerns,” said Denise A. Yardley, MD, GCRA, medical oncologist and Director of High-Risk at SCRI Oncology Partners and the Associate Director of Breast Cancer Research, Sarah Cannon Research Institute (SCRI). “With the launch of the SCRI Oncology Partners Center for Breast Health and our High-Risk Clinic, we’re bringing together top-tier expertise and compassionate care to support patients at every stage of their journey.”
A key feature of the new center is its High-Risk Clinic, which aims to help individuals understand their cancer risks and explain the role of hereditary cancer genetics, risk assessment and testing. A dedicated nurse practitioner guides each patient through the process of assessing their risk level. Individuals identified with elevated risk factors will be provided with personalized risk management recommendations and options for long-term surveillance. For patients who have already been diagnosed with breast cancer, a multidisciplinary team—including dedicated medical oncologists, radiologists, surgical oncologists, plastic surgeons, genetic counselors, oncology-certified nurse navigators, and leading research professionals—collaborate to deliver personalized, comprehensive care in a supportive environment.
Patients are cared for by a distinguished team of breast care specialists, including:
- Denise A. Yardley, MD, GCRA, medical oncologist and Director of High-Risk, SCRI Oncology Partners; Associate Director, Breast Cancer Research, SCRI
- Erika Hamilton, MD, medical oncologist, SCRI Oncology Partners; Director, Breast Cancer Research, SCRI
- Sarah Premji, MD, medical oncologist, SCRI Oncology Partners; Assistant Director, Breast Cancer Research, SCRI
- Mark Cooper, MD, breast surgeon, SCRI Oncology Partners
- A dedicated breast nurse navigator
This initiative continues the legacy of Sarah Cannon, known to many as Grand Ole Opry’s “Minnie Pearl.” After her own breast cancer journey, she lent her name to promote cancer research and education. Through its partnership with SCRI, SCRI Oncology Partners remains deeply committed to providing patients with access to early detection, innovative clinical trials, and a collaborative approach to care.
The SCRI Oncology Partners Center for Breast Health is located at 335 24th Avenue North, Suite 200, Nashville. For more information or to schedule an appointment, call 615-329-7345 or visit cancercarescri.com/.
About SCRI Oncology Partners
SCRI Oncology Partners is a leading cancer treatment center located in Nashville, Tennessee. Led by an elite team of globally recognized oncologists with specialized disease and clinical research expertise, this center offers patients state-of-the-art personalized cancer care and opportunities to participate in innovative clinical trials. Currently, there are hundreds of studies open for enrollment for all stages of cancer. SCRI Oncology Partners conducts clinical trials through a collaboration with Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI has contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade.
About The US Oncology Network
SCRI Oncology Partners is a part of The US Oncology Network (The Network), an organization of
approximately 3,300 independent providers committed to advancing high-quality, value-based
cancer care. As part of The Network, SCRI Oncology Partners engages in shared learning, clinical
collaboration, and continuous innovation to elevate the standard of care. Supported by
McKesson, The Network provides robust infrastructure and operational support, empowering
providers to focus on delivering compassionate, personalized care — close to home. SCRI Oncology Partners also participates in clinical trials through Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade.
###
Media contact: Kristie Foster, Executive Director
Email: Kristie.Foster@USOncology.com
Phone number: 405.312.3038